Skip to main
LPCN

Lipocine (LPCN) Stock Forecast & Price Target

Lipocine (LPCN) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lipocine Inc. has demonstrated significant advancements in its product pipeline, particularly with LPCN 1154, which presents an improved efficacy and safety profile over zuranolone, evidenced by a 61% remission rate at Day 3 and no adverse events of excessive sedation during clinical trials. The company is on track for a potential New Drug Application (NDA) submission for LPCN 1154 in the U.S. based on favorable topline data, which has increased the probability of approval to 50%. Despite a net loss of $3.2 million, Lipocine's ongoing innovations and strategic developments enhance its growth potential, underscoring a positive outlook for the company's future performance.

Bears say

Lipocine Inc reported a net loss of $3.2 million in the third quarter of 2025, raising concerns about its financial stability as it continues to invest in research and development. The company faces significant risks related to its LPCN 1154 product, including potential failure in clinical trials, the inability to secure regulatory approval, and challenges in achieving commercial success amid competition. Additionally, there is a looming dilution risk, which could further affect shareholder value and investor confidence.

Lipocine (LPCN) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lipocine and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lipocine (LPCN) Forecast

Analysts have given Lipocine (LPCN) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Lipocine (LPCN) has a Strong Buy consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lipocine (LPCN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.